MA50404A - Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées - Google Patents

Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées

Info

Publication number
MA50404A
MA50404A MA050404A MA50404A MA50404A MA 50404 A MA50404 A MA 50404A MA 050404 A MA050404 A MA 050404A MA 50404 A MA50404 A MA 50404A MA 50404 A MA50404 A MA 50404A
Authority
MA
Morocco
Prior art keywords
variant
icos
methods
associated compositions
ligand
Prior art date
Application number
MA050404A
Other languages
English (en)
Other versions
MA50404B1 (fr
Inventor
Lawrence Evans
Michael Kornacker
Ryan Swanson
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of MA50404A publication Critical patent/MA50404A/fr
Publication of MA50404B1 publication Critical patent/MA50404B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA50404A 2017-10-18 2018-10-17 Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées MA50404B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574161P 2017-10-18 2017-10-18
PCT/US2018/056381 WO2019079520A2 (fr) 2017-10-18 2018-10-17 Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
EP18803814.5A EP3697810B1 (fr) 2017-10-18 2018-10-17 Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées

Publications (2)

Publication Number Publication Date
MA50404A true MA50404A (fr) 2020-08-26
MA50404B1 MA50404B1 (fr) 2026-02-27

Family

ID=64316982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50404A MA50404B1 (fr) 2017-10-18 2018-10-17 Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées

Country Status (27)

Country Link
US (3) US20200283500A1 (fr)
EP (1) EP3697810B1 (fr)
JP (3) JP7282760B2 (fr)
KR (2) KR20250034197A (fr)
CN (1) CN111712515A (fr)
AR (1) AR113455A1 (fr)
AU (2) AU2018351000B2 (fr)
BR (1) BR112020007542A2 (fr)
CA (1) CA3078517A1 (fr)
DK (1) DK3697810T3 (fr)
EA (1) EA202090974A1 (fr)
FI (1) FI3697810T3 (fr)
HR (1) HRP20260069T1 (fr)
IL (2) IL320945A (fr)
LT (1) LT3697810T (fr)
MA (1) MA50404B1 (fr)
MX (1) MX2020004540A (fr)
MY (1) MY203416A (fr)
PH (1) PH12020550449A1 (fr)
PT (1) PT3697810T (fr)
RS (1) RS67712B1 (fr)
SA (1) SA520411779B1 (fr)
SG (1) SG11202003078VA (fr)
SM (1) SMT202600062T1 (fr)
TW (2) TW202500579A (fr)
UA (1) UA129833C2 (fr)
WO (1) WO2019079520A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283508B1 (fr) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à affinités accordables
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019241758A1 (fr) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
JP2022529059A (ja) * 2019-04-17 2022-06-16 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用
EP4008351A4 (fr) * 2019-08-02 2023-08-09 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anticorps anti-pd-1 et utilisation médicale associée
EP4021582A1 (fr) * 2019-08-30 2022-07-06 Allogene Therapeutics, Inc. Récepteurs de cytokines chimériques comprenant des domaines de liaison de tgf-bêta
IL292934A (en) * 2019-11-20 2022-07-01 Gi Cell Inc Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium
WO2021181233A2 (fr) * 2020-03-09 2021-09-16 Pfizer Inc. Protéines de fusion et leurs utilisations
BR112022022524A2 (pt) 2020-05-08 2022-12-13 Alpine Immune Sciences Inc Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
IL300524A (en) * 2020-08-12 2023-04-01 Migal Galilee Res Institute Ltd Allogeneic reactive immune cell exclusion device and its uses for protecting cells from a donor source from allogeneic rejection
KR20230155960A (ko) * 2022-05-03 2023-11-13 고려대학교 산학협력단 Icos와의 결합력이 향상된 icos-l 변이체

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
ATE248924T1 (de) 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
EP1005870B1 (fr) 1992-11-13 2009-01-21 Biogen Idec Inc. Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6361770B1 (en) 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
CA2230758A1 (fr) 1995-09-08 1997-03-13 Genzyme Corporation Vecteurs aav ameliores pour la therapie genique
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
CA2300957A1 (fr) 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus et vecteurs viraux
EP1015619A1 (fr) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Procedes et lignee cellulaire utiles pour la production de virus adeno-associes recombines
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
EP1218504B1 (fr) 1999-09-21 2007-07-11 Genetics Institute, LLC Molecules gl50 et leurs utilisations
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
EP1242116A2 (fr) 1999-12-22 2002-09-25 Onyx Pharmaceuticals, Inc. Mutants de glycoproteine c du virus herpes simplex 1 destines au traitement de la croissance de cellules hyperproliferatives non desirees
PT1252322E (pt) 2000-01-21 2005-03-31 Biovex Ltd Estirpes de virus de herpes para terapia genica
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
HRP20030071B1 (hr) 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
MXPA03010278A (es) 2001-05-11 2004-12-06 Wellstat Biologics Corp Terapia con virus oncolitico.
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
EP1411880B1 (fr) 2001-07-11 2018-04-25 University of Miami Vsv recombinant pour le traitement de cellules tumorales
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
ATE454447T1 (de) 2001-11-30 2010-01-15 Us Gov Health & Human Serv Peptidagonisten für prostata-spezifisches antigen und ihre verwendung
US7235631B2 (en) 2002-02-07 2007-06-26 Mayo Foundation For Medical Education And Research ICOS mutants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2479763A1 (fr) 2002-03-27 2003-10-09 Baylor College Of Medicine Virus herpes simplex oncolytique puissant pour une therapie du cancer
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
CA2489523A1 (fr) 2002-06-21 2003-12-31 Wellstat Biologics Corporation Administration de virus therapeutiques
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
WO2004022716A2 (fr) 2002-09-09 2004-03-18 University Of Tennessee Research Foundation Mutants recombines de rhabdovirus et leurs procedes d'utilisation
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
EP1606411B1 (fr) 2003-03-27 2008-12-10 Ottawa Health Research Institute Virus mutant de la stomatite vesiculaire et son utilisation
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
WO2005116224A2 (fr) 2004-05-18 2005-12-08 Children's Memorial Hospital Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (fr) 2004-06-24 2006-01-05 New York University Souches de virus d'herpes simplex oncolytique non virulent modifiees pour bloquer la reponse hote innee
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006033386A1 (fr) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha Anticorps igg4 humains stabilises
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
EP1885186B1 (fr) 2005-06-01 2015-09-02 California Institute Of Technology Procede permettant le transfert cible de genes au moyen de vecteurs viraux
CN105483093A (zh) 2005-06-23 2016-04-13 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
WO2008100292A2 (fr) 2006-10-16 2008-08-21 Genelux Corporation Souches du virus de la vaccine modifié pour une utilisation dans des procédés diagnostiques et thérapeutiques
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
WO2008099189A2 (fr) 2007-02-16 2008-08-21 Crusade Laboratories Limited Virus de l'herpès simplex et procédés de réplication virale
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
WO2008156655A2 (fr) 2007-06-15 2008-12-24 Genelux Corporation Microorganismes pour une imagerie et/ou un traitement de tumeurs
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
CN101784564B (zh) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-dc变体
EP2173368A1 (fr) 2007-07-18 2010-04-14 Genelux Corporation Utilisation d'un agent chimiothérapeutique dans la préparation d'un médicament pour traiter ou améliorer un effet secondaire indésirable associé à une thérapie virale oncolytique.
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
WO2009054996A2 (fr) 2007-10-25 2009-04-30 Genelux Corporation Systèmes et procédés pour une virothérapie
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
EP2225277A4 (fr) 2007-11-27 2012-03-14 Viventia Biotech Inc Anticorps dirigés contre un épitope associé au cancer de variant de nfkbib et ses utilisations
EP2222861B1 (fr) 2007-12-11 2017-12-06 The University of North Carolina At Chapel Hill Vecteurs rétroviraux modifiés dépourvus de sequence riche en polypurine (ppt)
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2307033A4 (fr) 2008-05-29 2012-06-13 Gen Hospital Corp Utilisation de virus herpes oncolytiques pour tuer des cellules souches cancéreuses
EP2398466B1 (fr) 2008-11-24 2021-02-17 Massachusetts Institute of Technology Procédés et compositions pour la délivrance localisée de nanoparticules vers de tumeurs
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
EP2283810A1 (fr) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Bactéries à administration orale en tant que véhicules pour l'administration systémique d'agents
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
HRP20140327T4 (hr) 2009-07-24 2017-11-03 Immune Design Corp Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
US8840889B2 (en) * 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
EP2482849B1 (fr) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Immunothérapie combinée pour le traitement du cancer
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2011097477A1 (fr) 2010-02-04 2011-08-11 The Trustees Of The University Of Pennsylvania Icos régule de façon critique l'expansion et la fonction des cellules inflammatoires humaines th17
HUE050768T2 (hu) 2010-02-19 2021-01-28 Xencor Inc Új CTLA4-IG immunadhezinek
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
WO2012149364A1 (fr) 2011-04-28 2012-11-01 Diamond Don J Vaccins associés aux tumeurs et compositions pour l'interruption de l'immunosuppression dérivée de tumeurs destinées à être utilisées en combinaison avec une immunothérapie contre le cancer
CN107519486B (zh) 2011-06-24 2021-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
WO2013001517A1 (fr) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
CA2848410A1 (fr) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Lymphocytes t a arn modifie pour le traitement du cancer
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
WO2013156054A1 (fr) * 2012-04-16 2013-10-24 Universität Stuttgart Domaine 2 de chaîne lourde d'igm et d'ige en tant que modules d'homodimérisation à liaison covalente pour la génération de protéines de fusion à double spécificité
KR102133060B1 (ko) 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
WO2014004857A1 (fr) 2012-06-27 2014-01-03 Orban Biotech Llc Protéines de fusion de ctla4 destinées au traitement du diabète
WO2014055657A1 (fr) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques
WO2014089113A1 (fr) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Amélioration de l'activité anticancéreuse de protéines de fusion de fc immuno-modulatrices
KR20150090919A (ko) 2012-12-04 2015-08-06 온코메드 파마슈티칼스, 인크. 결합제를 사용한 면역요법
WO2014138188A1 (fr) 2013-03-07 2014-09-12 The General Hospital Corporation Mutants de ctla4 humain et leur utilisation
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EA201591806A1 (ru) 2013-03-15 2016-01-29 Байоджен Ма Инк. Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
WO2014198002A1 (fr) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Bactérie produisant une protéine se liant à l'interféron et ses utilisations
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US20160271218A1 (en) 2013-06-27 2016-09-22 Mor Research Applications Ltd. Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
AU2014290288B2 (en) 2013-07-15 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
EP3043819A4 (fr) * 2013-09-11 2017-04-05 Compugen Ltd. Anticorps anti-vstm5 et leur utilisation à des fins thérapeutiques et diagnostiques
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
WO2015107026A1 (fr) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Variants de région fc présentant des propriétés modifiées de liaison à fcrn et des propriétés conservées de liaison à la protéine a
KR20160113268A (ko) 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
EP3105333B1 (fr) 2014-02-10 2020-04-08 Emory University Expression d'un polypeptide chimere comportant des recepteurs de lymphocytes variables sur des cellules immunitaires, et utilisations correspondantes dans le traitement du cancer
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP3194445A4 (fr) * 2014-08-04 2018-05-23 Baylor Research Institute Anticorps anti-ox40l antagonistes et leurs procédés d'utilisation
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
KR102812180B1 (ko) 2014-09-03 2025-05-23 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
AU2015343048A1 (en) 2014-11-06 2017-05-18 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
EP3020816A1 (fr) 2014-11-11 2016-05-18 University College Cork Thérapie génique à médiation bactérienne
WO2016118577A1 (fr) 2015-01-22 2016-07-28 Medimmune, Llc Protéines de fusion thymosine-bêta-4
JP6841812B2 (ja) 2015-04-02 2021-03-10 キャンキュア リミティド 免疫応答を惹起するための作用物質及び組成物
WO2016164428A1 (fr) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Antagonistes de la voie de signalisation de mort cellulaire programmée 1 (pd-1) basés sur des récepteurs
EP3283508B1 (fr) * 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à affinités accordables
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
CA2993429A1 (fr) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions et methodes pour therapies immuno-oncologiques
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016323069A1 (en) 2015-09-14 2018-04-12 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
SG10201912943RA (en) 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
EP3529361B1 (fr) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Protéines immunomodulatrices sécrétables de type variant et thérapie cellulaire utilisant des cellules obtenues par génie génétique
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
BR112020013236A2 (pt) * 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019241758A1 (fr) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
JP2022529059A (ja) 2019-04-17 2022-06-16 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用

Also Published As

Publication number Publication date
IL273726B2 (en) 2025-10-01
HRP20260069T1 (hr) 2026-02-27
TW201925223A (zh) 2019-07-01
RS67712B1 (sr) 2026-02-27
KR20200085777A (ko) 2020-07-15
PT3697810T (pt) 2026-02-19
AU2024201301A1 (en) 2024-03-21
AR113455A1 (es) 2020-05-06
KR102776394B1 (ko) 2025-03-10
JP7530457B2 (ja) 2024-08-07
CA3078517A1 (fr) 2019-04-25
EP3697810A2 (fr) 2020-08-26
EA202090974A1 (ru) 2020-08-05
JP2024103596A (ja) 2024-08-01
IL273726A (en) 2020-05-31
TW202500579A (zh) 2025-01-01
WO2019079520A2 (fr) 2019-04-25
SG11202003078VA (en) 2020-05-28
WO2019079520A3 (fr) 2019-05-23
US20230235012A1 (en) 2023-07-27
MA50404B1 (fr) 2026-02-27
KR20250034197A (ko) 2025-03-10
SMT202600062T1 (it) 2026-03-09
PH12020550449A1 (en) 2021-05-17
JP7282760B2 (ja) 2023-05-29
EP3697810B1 (fr) 2025-12-03
IL273726B1 (en) 2025-06-01
DK3697810T3 (da) 2026-02-02
JP2021500024A (ja) 2021-01-07
UA129833C2 (uk) 2025-08-20
BR112020007542A2 (pt) 2020-12-01
US11613566B2 (en) 2023-03-28
AU2018351000A1 (en) 2020-04-30
US20200283500A1 (en) 2020-09-10
CN111712515A (zh) 2020-09-25
FI3697810T3 (fi) 2026-02-05
SA520411779B1 (ar) 2024-03-17
MY203416A (en) 2024-06-27
MX2020004540A (es) 2020-08-03
TWI899046B (zh) 2025-10-01
US20220112265A1 (en) 2022-04-14
AU2018351000B2 (en) 2023-11-30
IL320945A (en) 2025-07-01
LT3697810T (lt) 2026-02-25
JP2023055821A (ja) 2023-04-18

Similar Documents

Publication Publication Date Title
MA50404A (fr) Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
EP3589662A4 (fr) Protéine monovalente inductible de fixation d' antigène
IL262365A (en) Icos ligand variant immunomodulatory proteins and uses thereof
PT3890382T (pt) Identificador de assinatura oculto
IL268920A (en) Peptide vaccines
EP3668689A4 (fr) Configuration de système d'interaction
IL268780A (en) Pd-l1 variant immunomodulatory proteins and uses thereof
PL3649151T3 (pl) Białka rusztowania
DK3565568T3 (da) Ændret virus
IL254516A0 (en) Proteins specific for cd137
EP3488069A4 (fr) Système d'écran
IL268815A (en) Compositions and methods for tumor transduction
EP3475167A4 (fr) Système de siège à agencement décalé
IL271111A (en) Liquid sample loading
EP3592914A4 (fr) Système de construction
EP3702925A4 (fr) Système de conférence
EP3596610A4 (fr) Système de cuisson
EP3532410A4 (fr) Convoyeur à vibrations
EP3639257C0 (fr) Dispositif secoueur
DK3582629T3 (da) Marinade
EP3359994A4 (fr) Système d'autopropulsion
EP3453650C0 (fr) Système de convoyeur
EP3562770A4 (fr) Système de transport
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
DK3496525T3 (da) Forarbejdningsenhed